Camber Pharmaceuticals Launches Generic Stendra®

Piscataway, NJ, October 29, 2024 – Camber Pharmaceuticals is excited to expand its product line with Avanafil Tablets. A study by the Cleveland Clinic reveals that about 40% of men experience erectile dysfunction (ED) by age 40, with this number rising to nearly 70% by age 70.
Avanafil Tablets is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction.
Avanafil Tablets are available in 50, 100 and 200 mg strengths in 30 count bottles.
To learn more about Avanafil Tablets, please visit www.camberpharma.com/avanafil
Recent articles
- Camber’s Parent Company, Hetero, Partners with the Gates Foundation to Supply Generic Lenacapavir for HIV Prevention
- Camber Adds 800 mg Darunavir Tablets to Product Family
- Camber Expands Portfolio with 10 New Generic Drug Launches in Q3 2025
- Camber Launches Indomethacin Suppositories
- Camber Launches Voriconazole for Injection
- Camber Launches Magnesium Sulfate Injection